CA1144841A - Methode et appareil pour traitement par hyperthermie - Google Patents

Methode et appareil pour traitement par hyperthermie

Info

Publication number: CA1144841A
Authority: CA; Canada
Prior art keywords: liquid; flow; patient; blood; heat exchanger
Prior art date: 1977-05-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000399707A

Other languages

English (en)

Inventor

Leon C. Parks

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

RESEARCH AGAINST CANCER Inc

Original Assignee

RESEARCH AGAINST CANCER Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1977-05-31

Filing date

1982-03-29

Publication date

1983-04-19

1977-05-31 Priority claimed from US05/802,033 external-priority patent/US4181132A/en

1982-03-29 Application filed by RESEARCH AGAINST CANCER Inc filed Critical RESEARCH AGAINST CANCER Inc

1982-03-29 Priority to CA000399707A priority Critical patent/CA1144841A/fr

1983-04-19 Application granted granted Critical

1983-04-19 Publication of CA1144841A publication Critical patent/CA1144841A/fr

Status Expired legal-status Critical Current

Links

238000000034 method Methods 0.000 title description 26
238000011282 treatment Methods 0.000 title description 19
230000002977 hyperthermial effect Effects 0.000 title description 8
239000007788 liquid Substances 0.000 claims abstract description 68
239000008280 blood Substances 0.000 claims abstract description 51
210000004369 blood Anatomy 0.000 claims abstract description 51
230000009885 systemic effect Effects 0.000 claims abstract description 20
238000005086 pumping Methods 0.000 claims abstract description 8
230000005907 cancer growth Effects 0.000 claims abstract description 4
206010020843 Hyperthermia Diseases 0.000 description 24
230000036031 hyperthermia Effects 0.000 description 24
239000007943 implant Substances 0.000 description 23
206010028980 Neoplasm Diseases 0.000 description 22
201000011510 cancer Diseases 0.000 description 21
239000000463 material Substances 0.000 description 15
230000000694 effects Effects 0.000 description 14
230000000712 assembly Effects 0.000 description 13
238000000429 assembly Methods 0.000 description 13
230000010412 perfusion Effects 0.000 description 9
238000010438 heat treatment Methods 0.000 description 8
230000001965 increasing effect Effects 0.000 description 8
238000004891 communication Methods 0.000 description 7
230000006854 communication Effects 0.000 description 7
210000003191 femoral vein Anatomy 0.000 description 7
230000002411 adverse Effects 0.000 description 6
238000000502 dialysis Methods 0.000 description 6
210000003414 extremity Anatomy 0.000 description 6
210000001105 femoral artery Anatomy 0.000 description 6
239000012530 fluid Substances 0.000 description 6
238000003780 insertion Methods 0.000 description 6
230000037431 insertion Effects 0.000 description 6
230000002792 vascular Effects 0.000 description 6
206010053567 Coagulopathies Diseases 0.000 description 5
210000001367 artery Anatomy 0.000 description 5
230000035602 clotting Effects 0.000 description 5
208000015181 infectious disease Diseases 0.000 description 5
230000002093 peripheral effect Effects 0.000 description 5
239000004033 plastic Substances 0.000 description 5
229920003023 plastic Polymers 0.000 description 5
238000007920 subcutaneous administration Methods 0.000 description 5
241001631457 Cannula Species 0.000 description 4
230000017531 blood circulation Effects 0.000 description 4
238000002512 chemotherapy Methods 0.000 description 4
238000001816 cooling Methods 0.000 description 4
239000004744 fabric Substances 0.000 description 4
230000036210 malignancy Effects 0.000 description 4
238000001356 surgical procedure Methods 0.000 description 4
210000003462 vein Anatomy 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
208000007536 Thrombosis Diseases 0.000 description 3
230000001093 anti-cancer Effects 0.000 description 3
239000013536 elastomeric material Substances 0.000 description 3
150000002500 ions Chemical class 0.000 description 3
201000001441 melanoma Diseases 0.000 description 3
230000001706 oxygenating effect Effects 0.000 description 3
230000002572 peristaltic effect Effects 0.000 description 3
238000001959 radiotherapy Methods 0.000 description 3
229920000260 silastic Polymers 0.000 description 3
229920004934 Dacron® Polymers 0.000 description 2
208000032843 Hemorrhage Diseases 0.000 description 2
230000000259 anti-tumor effect Effects 0.000 description 2
TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
230000000740 bleeding effect Effects 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
230000036757 core body temperature Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000002513 implantation Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
238000002955 isolation Methods 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
238000011275 oncology therapy Methods 0.000 description 2
239000005020 polyethylene terephthalate Substances 0.000 description 2
230000005855 radiation Effects 0.000 description 2
239000000523 sample Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
241000331231 Amorphocerini gen. n. 1 DAD-2008 Species 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
231100000699 Bacterial toxin Toxicity 0.000 description 1
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
241000937378 Everettia interior Species 0.000 description 1
206010015719 Exsanguination Diseases 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
102000003940 Occludin Human genes 0.000 description 1
108090000304 Occludin Proteins 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
101150110390 Slc10a6 gene Proteins 0.000 description 1
102000000763 Survivin Human genes 0.000 description 1
108010002687 Survivin Proteins 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
206010057040 Temperature intolerance Diseases 0.000 description 1
208000003443 Unconsciousness Diseases 0.000 description 1
229910000771 Vitallium Inorganic materials 0.000 description 1
238000002266 amputation Methods 0.000 description 1
230000003872 anastomosis Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
230000010455 autoregulation Effects 0.000 description 1
239000000688 bacterial toxin Substances 0.000 description 1
238000005452 bending Methods 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000012829 chemotherapy agent Substances 0.000 description 1
HGAZMNJKRQFZKS-UHFFFAOYSA-N chloroethene;ethenyl acetate Chemical compound ClC=C.CC(=O)OC=C HGAZMNJKRQFZKS-UHFFFAOYSA-N 0.000 description 1
230000004087 circulation Effects 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
238000010276 construction Methods 0.000 description 1
239000000110 cooling liquid Substances 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
239000007789 gas Substances 0.000 description 1
238000002695 general anesthesia Methods 0.000 description 1
239000003292 glue Substances 0.000 description 1
238000001631 haemodialysis Methods 0.000 description 1
230000008543 heat sensitivity Effects 0.000 description 1
230000000322 hemodialysis Effects 0.000 description 1
JCYWCSGERIELPG-UHFFFAOYSA-N imes Chemical class CC1=CC(C)=CC(C)=C1N1C=CN(C=2C(=CC(C)=CC=2C)C)[C]1 JCYWCSGERIELPG-UHFFFAOYSA-N 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011221 initial treatment Methods 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
YDTFRJLNMPSCFM-YDALLXLXSA-M levothyroxine sodium anhydrous Chemical compound [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 YDTFRJLNMPSCFM-YDALLXLXSA-M 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
125000002872 norbornadienyl group Chemical group C12=C(C=C(CC1)C2)* 0.000 description 1
238000002559 palpation Methods 0.000 description 1
229920001343 polytetrafluoroethylene Polymers 0.000 description 1
230000008569 process Effects 0.000 description 1
230000005180 public health Effects 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000005096 rolling process Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
230000035900 sweating Effects 0.000 description 1
230000001839 systemic circulation Effects 0.000 description 1
229920001897 terpolymer Polymers 0.000 description 1
239000012815 thermoplastic material Substances 0.000 description 1
229920001187 thermosetting polymer Polymers 0.000 description 1
SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
230000003582 thrombocytopenic effect Effects 0.000 description 1
201000005665 thrombophilia Diseases 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
239000000602 vitallium Substances 0.000 description 1

Landscapes

External Artificial Organs (AREA)

CA000399707A 1977-05-31 1982-03-29 Methode et appareil pour traitement par hyperthermie Expired CA1144841A (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA000399707A CA1144841A (fr)	1977-05-31	1982-03-29	Methode et appareil pour traitement par hyperthermie

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US05/802,033 US4181132A (en)	1977-05-31	1977-05-31	Method and apparatus for effecting hyperthermic treatment
US802,033		1977-05-31
CA303,444A CA1127033A (fr)	1977-05-31	1978-05-16	Methode et appareil pour effectuer un traitement par hypertermie
AU53195/79A AU518660B2 (en)	1977-05-31	1979-11-26	An elongate percutaneous cannula
CA000399707A CA1144841A (fr)	1977-05-31	1982-03-29	Methode et appareil pour traitement par hyperthermie

Publications (1)

Publication Number	Publication Date
CA1144841A true CA1144841A (fr)	1983-04-19

Family

ID=27423445

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000399707A Expired CA1144841A (fr)	1977-05-31	1982-03-29	Methode et appareil pour traitement par hyperthermie

Country Status (1)

Country	Link
CA (1)	CA1144841A (fr)

1982
- 1982-03-29 CA CA000399707A patent/CA1144841A/fr not_active Expired

Legal Events

Date	Code	Title	Description
2000-04-19	MKEX	Expiry

Publication	Publication Date	Title
US4181132A (en)	1980-01-01	Method and apparatus for effecting hyperthermic treatment
US4479798A (en)	1984-10-30	Subcutaneous implant useful in effecting hyperthermic treatment
US4476867A (en)	1984-10-16	Apparatus for effecting hyperthermic treatment
US4298006A (en)	1981-11-03	Systemic hyperthermia with improved temperature sensing apparatus and method
US3140716A (en)	1964-07-14	Heat exchanger for blood
JP4456764B2 (ja)	2010-04-28	熱交換留置カテーテル用冷却システム
Seneviratne	1949	Physiological and pathological responses in the blood‐vessels of the liver
US3425419A (en)	1969-02-04	Method of lowering and raising the temperature of the human body
US3826257A (en)	1974-07-30	Prosthetic shunt
US7189253B2 (en)	2007-03-13	Cerebral temperature control
US6981977B2 (en)	2006-01-03	Body fluid cartridge exchange platform device
AU2003248190A1 (en)	2003-10-30	Circulatory support system and method of use for isolated segmental perfusion
Work	2002	Hemodialysis catheters and ports
CA1144841A (fr)	1983-04-19	Methode et appareil pour traitement par hyperthermie
Hadaway	1995	Comparison of vascular access devices
CA1144836A (fr)	1983-04-19	Methode et appareil pour traitement par hyperthermie
CA1144837A (fr)	1983-04-19	Methode et appareil pour traitement par hyperthermie
CN220142014U (zh)	2023-12-08	一种多功能动静脉瘘术后康复锻炼支具
IE47074B1 (en)	1983-12-14	Apparatus for effecting hyperthermic treatment
Fish et al.	1969	Preparation of chronic thoracic duct lymph fistulas in man and laboratory animals
KR820000226B1 (ko)	1982-03-08	고열요법(hyperthermic treatment)장치
Gaggioti et al.	1986	Percutaneous vs. totally implantable catheters in home parenteral nutrition
CN217409126U (zh)	2022-09-13	术中用加温毯
Zhang et al.	2020	Application of Arm Infusion Port, Chest Wall Infusion Port and PICC in Chemotherapy of Blood Tumor.
TICE et al.	1963	Lumbar Sympathectomy: Effects on Vascular Responses in the Lower Extremity of Patients With Arteriosclerosis Obliterans